A prospective randomized clinical study of all morbidly obese patients undergoing SG, RYGB and OAGB, as primary bariatric procedures, was performed. Patients were randomly assigned into 3 groups: those patients undergoing SG, those ones undergoing RYGB and those ones undergoing OAGB. BMI, excess BMI loss (EBMIL) and remission of type 2 diabetes (T2DM), hypertension (HT) and dyslipidemia (DL) were assessed.

A prospective randomized clinical study of all morbidly obese patients undergoing SG, RYGB and OAGB, as primary bariatric procedures, was performed. Patients were randomly assigned into 3 groups: those patients undergoing Sleeve Gastrectomy, those ones undergoing Roux-en-Y Gastric Bypass and those ones undergoing One-Anastomosis Gastric Bypass. Body Mass Index (BMI), excess BMI loss (EBMIL) and remission of type 2 diabetes (T2DM), hypertension (HT) and dyslipidemia (DL) were assessed.

Inclusion Criteria:

• body mass index (BMI) >40 Kg/m2
• BMI > 35 Kg/m2 with the presence of comorbidities associated to obesity
• age older than 18 years
• Patients willing to participate in the study and giving their written consent

Exclusion Criteria:

• patients undergoing other bariatric techniques than SG, RYGB and OAGB
• Patients undergoing any other surgical procedure added to the bariatric surgery
• patients with medical or surgical pathologies that at the discretion of the investigators do not allow their participation in the study
• inability to understand the nature and purpose of the study and / or to accept written participation in the study
• impossibility to comply with pre-established clinical follow-up.